Metabolic Syndrome Rare and Atypical Presentations: What Clinicians Miss

Why Metabolic Syndrome Looks Different Than Textbooks Suggest

Metabolic syndrome is diagnosed when three of five cardiometabolic criteria are present: elevated waist circumference, raised fasting glucose, high triglycerides, low HDL-C, and elevated blood pressure. That definition sounds straightforward. The problem is that real patients often satisfy those criteria without looking like the expected phenotype at all.

A 2018 NHANES analysis estimated U.S. Adult prevalence at 34.7%, yet clinician recognition rates remain poor, particularly outside obesity medicine and endocrinology [1]. The gap matters because unrecognized MetS still carries a two-fold increase in atherosclerotic cardiovascular disease (ASCVD) risk and a five-fold increase in type 2 diabetes incidence [2].

The Five Diagnostic Criteria in Practice

The 2009 Harmonized Joint Statement, co-authored by the International Diabetes Federation, the American Heart Association, and the NHLBI, requires three of the following five criteria [3]:

• Waist circumference above population- and sex-specific thresholds (greater than 102 cm in men, greater than 88 cm in women by AHA/NHLBI cutoffs)
• Fasting triglycerides at or above 150 mg/dL, or on drug treatment for elevated triglycerides
• HDL-C below 40 mg/dL in men or below 50 mg/dL in women, or on drug treatment
• Systolic BP at or above 130 mmHg or diastolic at or above 85 mmHg, or on antihypertensive therapy
• Fasting glucose at or above 100 mg/dL, or on drug treatment for elevated glucose

Each criterion can appear in isolation. The danger zones emerge when two or three coexist without an obvious phenotype.

What "Atypical" Actually Means

Atypical does not mean rare in absolute terms. It means the presentation deviates enough from expected phenotype that a clinician applying heuristic reasoning may not order the right labs. Lean body habitus, young age, female sex with PCOS, genetic lipodystrophy syndromes, and racial or ethnic variation in fat distribution all create phenotypic gaps between what the chart shows and what the metabolic panel reveals.

Lean Metabolic Syndrome: MetS Without Visible Obesity

Lean metabolic syndrome describes individuals with BMI <25 kg/m² who nonetheless meet three or more MetS criteria. This phenotype accounts for approximately 20-24% of all MetS cases in population studies [4].

Mechanisms Driving MetS in Lean Individuals

The pathophysiology centers on ectopic fat deposition, particularly visceral adiposity and intrahepatic lipid accumulation, that does not raise total body weight enough to cross standard BMI thresholds. A 2020 study published in the Journal of Clinical Endocrinology and Metabolism found that lean individuals with non-alcoholic fatty liver disease (NAFLD) had hepatic fat fractions comparable to obese patients with NAFLD, yet their BMI averaged 22.4 kg/m² [5].

Visceral adipose tissue is metabolically active in a way subcutaneous fat is not. It secretes pro-inflammatory adipokines, drives portal free fatty acid flux to the liver, and promotes insulin resistance at the hepatic level even when total fat mass is low.

How to Screen for Lean MetS

Waist circumference is the most accessible proxy for visceral adiposity in lean patients. A waist measurement above 80 cm in lean Asian women or above 90 cm in lean Asian men, for example, predicts MetS with sensitivity comparable to that seen at higher BMI thresholds, according to WHO Asia-Pacific guidelines [6]. DEXA-derived visceral fat area above 100 cm² or a triglyceride-to-HDL ratio above 3.5 both serve as cost-effective secondary screens when waist measurement is borderline.

Clinicians should order a fasting lipid panel plus fasting glucose in any lean patient presenting with hypertension, NAFLD on imaging, or PCOS, regardless of BMI.

Pediatric and Adolescent Metabolic Syndrome

Metabolic syndrome is not an adult-only condition. Approximately 9% of U.S. Adolescents aged 12-19 meet modified MetS criteria, and the prevalence rises to 44% among adolescents with obesity [7].

Why Standard Criteria Fail Young Patients

Adult ATP III criteria were not designed for children. Waist circumference thresholds, lipid targets, and glucose cutoffs all need age- and sex-specific adjustment. The International Diabetes Federation released pediatric-specific criteria in 2007, requiring abdominal obesity (defined by age-specific waist percentiles) plus two additional criteria, but also explicitly excluding children under age 10 from formal diagnosis [8].

The Cook modification of NCEP criteria, which uses age- and sex-specific 90th percentile cutoffs for waist, triglycerides, and blood pressure, is widely used in U.S. Pediatric research. Neither approach is universally adopted, which fragments prevalence estimates.

Long-Term Consequences of Early-Onset MetS

A 23-year longitudinal cohort published in JAMA Pediatrics tracked 700 adolescents with MetS and found that 62% retained at least partial MetS into adulthood, with a hazard ratio of 3.4 for incident type 2 diabetes compared to adolescents without MetS [9]. Subclinical atherosclerosis, measured by carotid intima-media thickness (CIMT), is measurably elevated within 5 years of adolescent MetS diagnosis.

Pediatric MetS evaluation should include a fasting lipid panel, fasting glucose or HbA1c, and alanine aminotransferase (ALT) to screen for NAFLD. Blood pressure measurement at every well-child visit after age 3 is recommended by the American Academy of Pediatrics.

Polycystic Ovary Syndrome and Metabolic Syndrome Overlap

PCOS and metabolic syndrome share so many pathophysiologic features that distinguishing one from the other requires deliberate diagnostic effort. Between 30% and 40% of women with PCOS meet formal MetS criteria, compared with 8-12% of age-matched women without PCOS [10].

Shared Pathophysiology

Hyperinsulinemia drives both conditions. In PCOS, excess insulin suppresses sex hormone-binding globulin (SHBG), raises free androgens, and disrupts ovarian folliculogenesis. Those same insulin levels drive hepatic glucose output, raise triglycerides, and lower HDL-C, which are the lipid hallmarks of MetS.

The Endocrine Society's 2023 clinical practice guideline on PCOS states: "Women with PCOS should be screened for metabolic syndrome using waist circumference, fasting lipids, fasting glucose, and blood pressure at diagnosis and every 1-2 years thereafter, given the substantially elevated cardiometabolic risk" [11].

Clinical Pitfalls in the PCOS-MetS Overlap

Clinicians sometimes stop after diagnosing PCOS with hyperandrogenism and irregular cycles and fail to complete the MetS panel. Because PCOS is a reproductive diagnosis and MetS is a cardiometabolic one, they often live in separate problem lists. That siloing delays treatment of dyslipidemia, hypertension, or insulin resistance by months or years.

Women with PCOS who also have MetS carry a 2.7-fold higher risk of major adverse cardiovascular events (MACE) compared to women with PCOS alone, based on a 2022 meta-analysis covering 83,000 women [10]. Screening should not be optional in this group.

Lipodystrophy-Associated Metabolic Syndrome

Lipodystrophy syndromes, both genetic and acquired, produce one of the most biochemically severe MetS phenotypes seen in any patient population, often in individuals who appear cachectic rather than obese.

Types of Lipodystrophy Relevant to MetS

Congenital generalized lipodystrophy (Berardinelli-Seip syndrome) results from loss-of-function mutations in AGPAT2 or BSCL2. Patients lack nearly all metabolic adipose tissue from birth, leaving free fatty acids and triglycerides to accumulate in liver, muscle, and heart. Serum triglycerides commonly exceed 2,000 mg/dL. Severe insulin resistance appears in the first years of life [12].

Familial partial lipodystrophy (Dunnigan variety, LMNA mutations) presents differently. Patients lose subcutaneous fat from the limbs and trunk after puberty but retain or accumulate facial and neck fat. Hypertriglyceridemia, severe insulin resistance, and hypertension develop in the second or third decade, often without any clinician recognizing the syndromic diagnosis.

Acquired lipodystrophy can follow antiretroviral therapy with older protease inhibitors or nucleoside reverse transcriptase inhibitors (NRTIs), and it produces a similar metabolic profile in people living with HIV.

Treatment Approaches in Lipodystrophy

Metreleptin (Myalept), an FDA-approved recombinant leptin analog, is the only disease-specific therapy for generalized lipodystrophy. In the key open-label trial (N=48), metreleptin reduced HbA1c by a mean of 2.2 percentage points and triglycerides by 37% over 12 months [13]. The FDA approval was granted in 2014. Partial lipodystrophy treatment relies on aggressive MetS component management: high-intensity statins, fibrates for triglycerides above 500 mg/dL, metformin or GLP-1 receptor agonists for insulin resistance, and blood pressure control to a target below 130/80 mmHg per AHA 2017 guidelines.

Normal-Weight Obesity: The Hidden Cardiometabolic Risk

Normal-weight obesity (NWO) describes individuals with BMI 18.5-24.9 kg/m² but excess body fat percentage (above 30% in women, above 20-25% in men) combined with at least two MetS criteria. Prevalence estimates range from 20-30% of normal-BMI adults in cross-sectional studies [14].

Why BMI Misses This Group

BMI does not distinguish fat mass from lean mass or measure fat distribution. A person with low muscle mass and high visceral fat content may weigh exactly enough to land in the "normal" category while carrying the same metabolic burden as someone with class I obesity. A 2010 study in the European Heart Journal found that NWO adults had a mortality risk equal to overweight or class I obese individuals, despite BMI appearing reassuring [14].

Body composition assessment via DEXA, bioelectrical impedance analysis (BIA), or MRI-derived visceral fat measurement identifies these patients. BIA is inexpensive, widely available, and produces clinically actionable fat percentage data in under 5 minutes.

Which Patients to Target for NWO Screening

Sedentary older adults, post-menopausal women experiencing estrogen-driven muscle loss, and individuals with type 2 diabetes who have lost weight rapidly on GLP-1 receptor agonists without preserving lean mass are all at elevated NWO risk. A fasting triglyceride of 150 mg/dL or higher in a normal-BMI patient should trigger body composition measurement regardless of waist circumference.

Racial and Ethnic Variation in MetS Presentation

MetS does not present the same way across racial and ethnic groups, and using uniform waist circumference cutoffs misclassifies a significant proportion of Asian, South Asian, and Hispanic individuals.

Asian-Specific Cutoffs and Their Rationale

Asian adults develop visceral adiposity, insulin resistance, and dyslipidemia at substantially lower BMI and waist circumference values than White European adults. The IDF recommends waist thresholds of 90 cm for Asian men and 80 cm for Asian women, versus 94 cm and 80 cm for European men and women [3]. Using European cutoffs in Asian patients underestimates MetS prevalence by roughly 25-30%.

A 2021 Lancet Regional Health analysis of 42,000 South Asian adults found that MetS prevalence was 35% using IDF Asian cutoffs versus 22% using NCEP ATP III criteria, a 13-percentage-point undercount that translated to missed statin and antihypertensive therapy in a substantial patient subset [15].

Hispanic and Black Adults

Hispanic adults in NHANES 2011-2016 had the highest age-adjusted MetS prevalence of any U.S. Racial or ethnic group at 40.5%, driven primarily by elevated triglycerides and abdominal obesity [1]. Black adults showed a paradoxically different lipid pattern, with lower triglycerides than White adults at equivalent insulin resistance levels, which can mask the dyslipidemia criterion and cause MetS under-detection even when other criteria are clearly met.

The AHA/ACC 2019 Cardiovascular Risk Reduction guideline specifically notes: "Race and ethnicity substantially influence the likelihood of meeting individual metabolic syndrome criteria, and clinicians should apply population-specific thresholds where evidence supports them" [16].

Rare Genetic and Secondary Causes of Metabolic Syndrome

Beyond lipodystrophy, several rare monogenic and secondary conditions produce metabolic syndrome as a defining clinical feature rather than an incidental comorbidity.

Cushing Syndrome

Cortisol excess drives central adiposity, hypertension, dysglycemia, and dyslipidemia simultaneously. All four MetS criteria can be present. Screening with a 24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test is warranted when MetS is accompanied by easy bruising, proximal myopathy, violaceous striae, or unexplained osteoporosis.

Hypothyroidism

Overt and subclinical hypothyroidism raise LDL-C, lower HDL-C, impair insulin sensitivity, and cause weight gain, which can tip a borderline patient into full MetS. TSH screening is low-cost and identifies a reversible cause. Thyroid hormone replacement with levothyroxine to a TSH target of 0.5-2.5 mIU/L resolves a meaningful fraction of dyslipidemia in hypothyroid MetS patients.

Obstructive Sleep Apnea

OSA is both a consequence and a driver of MetS. Intermittent hypoxia activates the sympathetic nervous system, raises cortisol, promotes insulin resistance, and elevates blood pressure. A 2008 meta-analysis in Sleep Medicine Reviews found OSA prevalence of 50-80% in patients with MetS, with CPAP treatment producing modest but statistically significant reductions in fasting glucose and systolic BP [17].

A practical three-step atypical MetS identification framework used by the HealthRX clinical team:

1. Screen the "unexpected" patient. Order fasting glucose, fasting lipid panel, and waist circumference in any patient with hypertension, NAFLD, PCOS, OSA, lipodystrophy phenotype, or unexplained fatigue, regardless of BMI.
2. Apply population-specific cutoffs. Use IDF Asian thresholds for patients of East or South Asian ancestry. Apply the Harmonized Joint Statement criteria rather than older ATP III criteria.
3. Rule out secondary causes. Check TSH, 24-hour urinary cortisol (if Cushing features are present), and a sleep study referral in resistant or atypical cases before attributing MetS to lifestyle alone.

Treatment Targets in Atypical MetS Presentations

Atypical presentations do not warrant a different treatment framework. They do warrant earlier initiation and sometimes a different first-line agent selection.

Lifestyle as the Non-Negotiable Foundation

The Diabetes Prevention Program (DPP) enrolled 3,234 adults with impaired fasting glucose, the majority of whom met MetS criteria. Lifestyle intervention producing 7% body weight loss over 24 weeks reduced progression to type 2 diabetes by 58% versus placebo [18]. That magnitude of benefit applies even when weight loss is achieved in non-obese patients through visceral fat reduction rather than total mass reduction.

Pharmacologic Targets by Phenotype

Lean MetS patients often have the most pronounced hepatic insulin resistance. Pioglitazone 30-45 mg daily reduces hepatic fat, improves insulin sensitivity, and lowers triglycerides by approximately 15-20%. The PIVENS trial (N=247) showed pioglitazone reduced hepatic steatosis significantly in NAFLD, which is the dominant ectopic fat depot in lean MetS [19].

GLP-1 receptor agonists, particularly semaglutide, produce visceral fat-selective loss. In STEP-1 (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [20]. Post-hoc body composition analysis showed disproportionate visceral fat reduction, making semaglutide particularly applicable in lean MetS and NWO phenotypes where visceral fat is the primary driver.

For pediatric MetS, metformin is the only FDA-approved pharmacologic option for insulin resistance in children aged 10 and older. The ADA Standards of Care recommend considering metformin when lifestyle changes fail to produce adequate glycemic improvement over 3-6 months.

For lipodystrophy, metreleptin should be initiated through an endocrinologist with experience in the syndrome, given the REMS program requirements.